|drug549||COVID-19 Specific T Cell derived exosomes (CSTC-Exo) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This study compares SARS-CoV-2 immune responses in high pretest probability swab negative hospitalized PUI patients vs. low pretest probability swab negative hospitalized APS (Asymptomatic Persons being Screened) patients to try to understand the appropriateness and safety of clinical decisions made in these patient populations based on swab results.
Description: Qualitative seroconversion response rates (RR) in NP SARS-CoV-2 PCR swab negative PUI vs. swab negative APS patients will be compared as the primary outcome measurement.Measure: SARS-CoV-2 IgG Time: 120 days
Description: mRNA gene expression by RNAseq from whole blood collected into PAXGene RNA tubesMeasure: host immune response Time: 120 Days
Description: identification of a signature of differentially expressed host genes or antigen/epitope specific antibody or cellular responses.Measure: pathogen protein expression Time: 120 days